[HTML][HTML] Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …
exceeds 35 years in young patients, but its natural history might be interrupted by …
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
M Marchetti, AM Vannucchi, M Griesshammer… - The Lancet …, 2022 - thelancet.com
Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
EJ Duncavage, A Bagg, RP Hasserjian… - Blood, The Journal …, 2022 - ashpublications.org
Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic
cells driven by somatic gene mutations. Although assessment of morphology plays a crucial …
cells driven by somatic gene mutations. Although assessment of morphology plays a crucial …
Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera
M Kremyanskaya, AT Kuykendall… - … England Journal of …, 2024 - Mass Medical Soc
Background Polycythemia vera is a chronic myeloproliferative neoplasm characterized by
erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory …
erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory …
Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial
CN Harrison, J Nangalia, R Boucher… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/
hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV …
hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV …
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management
Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …
The international consensus classification of myeloid neoplasms and acute leukemias: myeloproliferative neoplasms
J Thiele, HM Kvasnicka, A Orazi… - American journal of …, 2023 - Wiley Online Library
A group of international experts, including hematopathologists, oncologists, and geneticists
were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World …
were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World …
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
J Mascarenhas, HE Kosiorek, JT Prchal… - Blood, The Journal …, 2022 - ashpublications.org
The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera
(PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and …
(PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and …
[HTML][HTML] Molecular pathogenesis of the myeloproliferative neoplasms
G Greenfield, MF McMullin, K Mills - Journal of Hematology & Oncology, 2021 - Springer
The Philadelphia negative myeloproliferative neoplasms (MPN) compromise a
heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera …
heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera …
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
T Barbui, AM Vannucchi, V De Stefano… - The Lancet …, 2021 - thelancet.com
Background There is no evidence that phlebotomy alone is sufficient to steadily maintain
haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to …
haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to …